Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Assessment of Drug Sensitivity in Hematopoietic Stem and Progenitor Cells From Acute Myelogenous Leukemia and Myelodysplastic Syndrome Ex Vivo.

Knorr KL, Finn LE, Smith BD, Hess AD, Foran JM, Karp JE, Kaufmann SH.

Stem Cells Transl Med. 2016 Nov 7. pii: sctm.2016-0034. [Epub ahead of print]

PMID:
27821554
2.

Prevalence of BCL-2/J(H) Translocation in Healthy African Americans.

Colon-Otero G, Van Wier SA, Ahmann GJ, Braggio E, Albertie ML, Weis JA, Ailawadhi S, Cerhan JR, Vishnu P, Jorgensen MS, Foran JM, Thomas CS, Fonseca R.

Ann Hematol. 2017 Jan;96(1):51-55. doi: 10.1007/s00277-016-2842-4.

PMID:
27730341
3.

Phase I study of single-agent CC-292, a highly selective Bruton's tyrosine kinase inhibitor, in relapsed/refractory chronic lymphocytic leukemia.

Brown JR, Harb WA, Hill BT, Gabrilove J, Sharman JP, Schreeder MT, Barr PM, Foran JM, Miller TP, Burger JA, Kelly KR, Mahadevan D, Ma S, Li Y, Pierce DW, Barnett E, Marine J, Miranda M, Azaryan A, Yu X, Nava-Parada P, Mei J, Kipps TJ.

Haematologica. 2016 Jul;101(7):e295-8. doi: 10.3324/haematol.2015.140806. No abstract available.

4.

Are we curing more older adults with acute myeloid leukemia with allogeneic transplantation in CR1?

Finn LE, Foran JM.

Curr Opin Hematol. 2016 Mar;23(2):95-101. doi: 10.1097/MOH.0000000000000220. Review.

PMID:
26825695
5.

The Hedgehog pathway as targetable vulnerability with 5-azacytidine in myelodysplastic syndrome and acute myeloid leukemia.

Tibes R, Al-Kali A, Oliver GR, Delman DH, Hansen N, Bhagavatula K, Mohan J, Rakhshan F, Wood T, Foran JM, Mesa RA, Bogenberger JM.

J Hematol Oncol. 2015 Oct 20;8:114. doi: 10.1186/s13045-015-0211-8.

6.

Health Insurance-Related Disparities in Lymphoma Survival Are Partly Mediated by Baseline Clinical Factors.

Olszewski AJ, Foran JM.

Oncologist. 2015 Oct;20(10):1223-4. doi: 10.1634/theoncologist.2015-0228. No abstract available.

7.

Etiologic heterogeneity among non-Hodgkin lymphoma subtypes: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Morton LM, Slager SL, Cerhan JR, Wang SS, Vajdic CM, Skibola CF, Bracci PM, de Sanjosé S, Smedby KE, Chiu BC, Zhang Y, Mbulaiteye SM, Monnereau A, Turner JJ, Clavel J, Adami HO, Chang ET, Glimelius B, Hjalgrim H, Melbye M, Crosignani P, di Lollo S, Miligi L, Nanni O, Ramazzotti V, Rodella S, Costantini AS, Stagnaro E, Tumino R, Vindigni C, Vineis P, Becker N, Benavente Y, Boffetta P, Brennan P, Cocco P, Foretova L, Maynadié M, Nieters A, Staines A, Colt JS, Cozen W, Davis S, de Roos AJ, Hartge P, Rothman N, Severson RK, Holly EA, Call TG, Feldman AL, Habermann TM, Liebow M, Blair A, Cantor KP, Kane EV, Lightfoot T, Roman E, Smith A, Brooks-Wilson A, Connors JM, Gascoyne RD, Spinelli JJ, Armstrong BK, Kricker A, Holford TR, Lan Q, Zheng T, Orsi L, Dal Maso L, Franceschi S, La Vecchia C, Negri E, Serraino D, Bernstein L, Levine A, Friedberg JW, Kelly JL, Berndt SI, Birmann BM, Clarke CA, Flowers CR, Foran JM, Kadin ME, Paltiel O, Weisenburger DD, Linet MS, Sampson JN.

J Natl Cancer Inst Monogr. 2014 Aug;2014(48):130-44. doi: 10.1093/jncimonographs/lgu013.

8.

Medical history, lifestyle, family history, and occupational risk factors for diffuse large B-cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Cerhan JR, Kricker A, Paltiel O, Flowers CR, Wang SS, Monnereau A, Blair A, Dal Maso L, Kane EV, Nieters A, Foran JM, Miligi L, Clavel J, Bernstein L, Rothman N, Slager SL, Sampson JN, Morton LM, Skibola CF.

J Natl Cancer Inst Monogr. 2014 Aug;2014(48):15-25. doi: 10.1093/jncimonographs/lgu010.

9.

Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study.

Nowakowski GS, LaPlant B, Macon WR, Reeder CB, Foran JM, Nelson GD, Thompson CA, Rivera CE, Inwards DJ, Micallef IN, Johnston PB, Porrata LF, Ansell SM, Gascoyne RD, Habermann TM, Witzig TE.

J Clin Oncol. 2015 Jan 20;33(3):251-7. doi: 10.1200/JCO.2014.55.5714.

PMID:
25135992
10.

Frontline therapy of AML: should the older patient be treated differently?

Foran JM.

Curr Hematol Malig Rep. 2014 Jun;9(2):100-8. doi: 10.1007/s11899-014-0211-8. Review.

PMID:
24838493
11.

Socioeconomic disparities in mortality after diffuse large B-cell lymphoma in the modern treatment era.

Tao L, Foran JM, Clarke CA, Gomez SL, Keegan TH.

Blood. 2014 Jun 5;123(23):3553-62. doi: 10.1182/blood-2013-07-517110.

12.

Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Cortes JE, Kantarjian H, Foran JM, Ghirdaladze D, Zodelava M, Borthakur G, Gammon G, Trone D, Armstrong RC, James J, Levis M.

J Clin Oncol. 2013 Oct 10;31(29):3681-7. doi: 10.1200/JCO.2013.48.8783.

13.

Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research.

Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Pérez WS, Bolwell BJ, Bornhäuser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litzow MR, Maharaj D, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ.

Biol Blood Marrow Transplant. 2013 Jul;19(7):1102-8. doi: 10.1016/j.bbmt.2013.04.022.

14.

Rituximab use and survival after diffuse large B-cell or follicular lymphoma: a population-based study.

Keegan TH, Moy LM, Foran JM, Alizadeh AA, Chang ET, Shema SJ, Schupp CW, Clarke CA, Glaser SL.

Leuk Lymphoma. 2013 Apr;54(4):743-51. doi: 10.3109/10428194.2012.727415.

PMID:
22957852
15.

Clinical presentation, diagnosis, and prognosis of myelodysplastic syndromes.

Foran JM, Shammo JM.

Am J Med. 2012 Jul;125(7 Suppl):S6-13. doi: 10.1016/j.amjmed.2012.04.015. Review.

PMID:
22735753
16.

Gemtuzumab: time to bring back on the market?

Foran JM.

Clin Adv Hematol Oncol. 2012 May;10(5):326-7. No abstract available.

PMID:
22706544
17.

Targeted therapy of acute myeloid leukemia in 2012: towards individualized therapy.

Foran JM.

Hematology. 2012 Apr;17 Suppl 1:S137-40. doi: 10.1179/102453312X13336169156456.

PMID:
22507802
18.

Primary central nervous system B cell lymphoma with features intermediate between diffuse large B cell lymphoma and Burkitt lymphoma.

Jiang L, Li Z, Finn LE, Personnet DA, Edenfield B, Foran JM, Jaeckle KA, Reimer R, Menke DM, Ketterling RP, Tun HW.

Int J Clin Exp Pathol. 2012;5(1):72-6.

19.

A case of acute promyelocytic leukemia without RARα rearrangement and apparently normal cytogenetics.

Vaklavas C, Steciuk MR, Ren Y, Baird MF, Mikhail FM, Foran JM.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):521-4. doi: 10.1016/j.clml.2011.03.036. No abstract available.

PMID:
21729689
20.

Acute myeloid leukemia.

O'Donnell MR, Abboud CN, Altman J, Appelbaum FR, Coutre SE, Damon LE, Foran JM, Goorha S, Maness LJ, Marcucci G, Maslak P, Millenson MM, Moore JO, Ravandi F, Shami PJ, Smith BD, Stone RM, Strickland SA, Tallman MS, Wang ES; National Comprehensive Cancer Network..

J Natl Compr Canc Netw. 2011 Mar;9(3):280-317. No abstract available.

PMID:
21393440
Items per page

Supplemental Content

Loading ...
Support Center